What Sets SciClone's FCPA Derivative Suit Apart

Law360, New York (November 23, 2011, 12:13 PM EST) -- On Oct. 3, 2011, SciClone Pharmaceuticals Inc., a California specialty pharmaceutical company with substantial commercial business in China, entered into a stipulation of settlement in connection with several consolidated derivative lawsuits pending against certain members of its staff of current and former directors and officers.

These suits were initially filed following an announcement by SciClone that the U.S. Securities and Exchange Commission and the U.S. Department of Justice were conducting formal investigations, which are currently ongoing, into possible violations of the Foreign Corrupt Practices Act with...
To view the full article, register now.